|
ANAB | Anaptysbio, Inc |
|
|
ANAB | Anaptysbio, Inc |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -0.02 |
| Leverage | 108.33% |
| Market Cap | $ 1.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -84.9m |
| Margin | -48.81% |
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.